BIOMÉRIEUX

# HSV1&2 VZV R-GENE®

**REAL TIME PCR ASSAYS - ARGENE® TRANSPLANT RANGE**

## The power of true experience


PIONEERING DIAGNOSTICS

# HSV1&2 VZV R-GENE®

## KEY FEATURES

- Ready-to-use reagents
- Complete qualitative and quantitative kit
- Simultaneous detection and quantification of HSV1 and HSV2
- Detection and quantification of VZV
- Validated on most relevant sample types
- Validated with the major extraction and amplification platforms
- Designed for low to high throughput analysis
- Same procedure for all the ARGENE® Transplant kits

## CLINICAL CONTEXT [1-5]

Herpes Simplex Viruses (HSV) 1 and 2 and Varicella-Zoster Virus (VZV) are DNA viruses belonging to the *Herpesviridae* family. Primary infection is generally limited to the mucous membranes and the skin. After primary infection, the virus persists in the host by establishing a latent infection. In case of chronic or transient immunosuppression, the virus may reactivate to generate recurrent infection. Usually benign, the infections with these viruses can develop in severe clinical forms such as encephalitis, meningitis, retinitis, fulminant hepatitis, bronchopneumonia and neonatal infections.

Various antivirals have proven their efficacy in treating these pathologies when prescribed early and at appropriate doses. In case of severe infections, it is therefore essential to obtain an early and rapid diagnosis of the infection.

## TECHNICAL INFORMATION

| ORDERING INFORMATION | HSV1&2 VZV R-GENE® - Ref. 69-014B | | |
|---|---|---|---|
| Parameters | HSV1 | HSV2 | VZV |
| Gene target | US7 | UL27 | gp19 protein |
| Validated specimens | CSF, Whole blood, Plasma, BAL, Mucocutaneous swabs (*qualitative only*), Anogenital swabs (*qualitative only*), Throat swabs (*qualitative only*) | CSF, Whole blood, Plasma, BAL , Mucocutaneous swabs (*qualitative only*), Anogenital swabs (*qualitative only*), Throat swabs (*qualitative only*) | CSF, Whole blood, Plasma, Mucocutaneous swabs (*qualitative only*) |
| Limit of Detection (LoD 95%) | CSF: 2.4 $\log_{10}$ copies/mL<br>Whole Blood, Plasma, BAL:<br>2.7 $\log_{10}$ copies/mL<br>Swabs: 3.0 $\log_{10}$ copies/mL | CSF: 2.0 $\log_{10}$ copies/mL<br>Whole Blood, Plasma, BAL:<br>2.0 $\log_{10}$ copies/mL<br>Swabs: 3.0 $\log_{10}$ copies/mL | CSF: 2.5 $\log_{10}$ copies/mL<br>Whole Blood, Plasma:<br>2.7 $\log_{10}$ copies/mL<br>Swabs: 3.0 $\log_{10}$ copies/mL |
| Quantification Range | CSF: 2.4 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL<br>Whole blood, Plasma, BAL :<br>2.7 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL | CSF: 2.0 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL<br>Whole blood, Plasma, BAL:<br>2.7 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL | CSF: 2.7 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL<br>Whole blood, Plasma :<br>2.7 $\log_{10}$ to 8.0 $\log_{10}$ copies/mL |
| Type of kit | Real-time detection and quantification kit | | |
| Validated extraction platforms | EMAG®, NUCLISENS® easyMAG®, MagNA Pure 96, QIAsymphony SP | | |
| Validated amplification platforms | ABI 7500 Fast, ABI 7500 Fast Dx, LightCycler 480 (System II), Rotor-Gene Q, CFX96 | | |
| Controls included | Extraction / Inhibition Control, Negative Control, Positive Control (QS3), 4 Quantification Standards, Sensitivity Control | | |
| PCR Protocol | Same PCR program as other ARGENE® Transplant kits<br>Same PCR program as ENTEROVIRUS R-GENE® and Parechovirus R-GENE® | | |
| Number of tests | 60 tests for HSV1&2, 60 tests for VZV | | |
| Storage conditions | -15°C / -31°C | | |
| Regulatory status | For *in vitro* diagnostic use, CE-IVD marking | | |

## OTHER ARGENE® TRANSPLANT KITS

• EBV R-GENE® (69-002B) • CMV R-GENE® (69-003B) • HHV6 R-GENE® (69-006B)
• ADENOVIRUS R-GENE® (69-010B) • BK Virus R-GENE® (69-013B) • Parvovirus B19 R-GENE® (69-019B) • HSV1 HSV2 R-GENE® (71-021) • VZV R-GENE® (71-022)

## OTHER ARGENE® KITS

• ENTEROVIRUS R-GENE® (69-005B)
• Parechovirus R-GENE® (71-020)


REFERENCES

1. Kumar et al. Pathogenesis and life cycle of herpes simplex virus infection-stages of primary, latency and recurrence. Journal of Oral and Maxillofacial Surgery, Medecine, and Pathology 2016; 28: 350-353
2. Zerboni et al. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014; 12(3): 197-210
3. Burrel S, Boutolleau D. Virus herpes simplex. EMC – Maladies infectieuses 2014; 11(4): 1-19
4. Widener et al. Herpes simplex virus. Handbook of Clinical Neurology 2014; 123(11): 251-263
5. Wang et al. Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Litterature. Front Immunol 2018; 9(1632) : 1-11



bioMérieux S.A. • 69280 Marcy l'Etoile • France • Tél.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90
**www.biomerieux.com**



08/19 9317227 007/GB/A / BIOMÉRIEUX, the BIOMÉRIEUX logo, ARGENE, EMAG, easyMAG, NUCLISENS and R-GENE are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.
Any other name or trademark is the property of its respective owner / bioMérieux S.A. RCS Lyon 673 620 399 / Printed in France / **thera** / RCS Lyon B 398 160 242